Health · 4 June 2026

New ovarian cancer drug approved for 400 women

Hundreds of women in England with advanced ovarian cancer can now get a new life-extending drug, the first in over 20 years. NHS England approved mirvetuximab soravtansine, a targeted therapy, after NICE recommended it for patients whose cancer resists chemotherapy. This new treatment helped patients live 16.5 months on average, compared to 12.8 months with standard chemotherapy.

By BriefTea Editorial · 4 June 2026 at 11:34

Reported by Guardian · How we write briefs

Get the app

Understand this story

How do drugs get approved? How are new drugs approved? How do new drugs get approved?

More briefs

HealthMany NHS Trusts Turn Down Palantir's Patient Data Platform TechnologyRussian Suspect in Deadly London Hospitals Hack Held in Germany HealthGreat Ormond Street's Same-Day Test Finds Hidden Infections in Sick Children HealthImmune cell found to kill small cell lung cancer in lab tests HealthDiabetics sleeping 8+ hours face nearly double kidney disease risk HealthNo perfect age to start HRT, but benefits peak before 60, experts say More health stories → Browse all stories →